ReviewInternational journal of molecular sciences2022
Neuropilin (NRPs) Related Pathological Conditions and Their Modulators.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications.Clinical and molecular hepatology · 2023Pooled it
- Machine learning-assisted identification and validation of NRP1 inhibitors through molecular docking and dynamics simulations.Scientific reports · 2026Article
- Regulatory role of neuronal guidance proteins in spinal cord injury.Neural regeneration research · 2026Article
- Crosstalk between NRP1 and autophagy in the tumor microenvironment: from molecular mechanisms to therapeutic targeting.Frontiers in immunology · 2026Review
- Pain Signaling by GPCRs and RTKs.Trends in pharmacological sciences · 2025Review
- Neuropilin Antagonists (NRPas) Block the Phosphorylation of the Cancer Therapeutic Key Factor p38α Kinase Triggering Cell Death.Molecules (Basel, Switzerland) · 2025Article
- Neuropilin1-dependent paracrine signaling of cancer cells mediated by miRNA exosomal cargo.Cell communication and signaling : CCS · 2025Article
- Differential neuropilin isoform expressions highlight plasticity in macrophages in the heterogenous TME throughFrontiers in immunology · 2025Article
- Article
- Identification of novel pQTL-SNPs associated with lung adenocarcinoma risk: A multi-stage study.Cancer medicine · 2024Article
- Orchestrating Resilience: How Neuropilin-2 and Macrophages Contribute to Cardiothoracic Disease.Journal of clinical medicine · 2024Review
- Article
- New Biosensor for Determination of Neuropilin-1 with Detection by Surface Plasmon Resonance Imaging.Sensors (Basel, Switzerland) · 2023Article
- NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation.Cell death & disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Neuropilin 1 (NRP1) represents one of the two homologous neuropilins (NRP, splice variants of neuropilin 2 are the other) found in all vertebrates. It forms a transmembrane glycoprotein distributed in many human body tissues as a (co)receptor for a variety of different ligands. In addition to its physiological role, it is also associated with various pathological conditions. Recently, NRP1 has been discovered as a coreceptor for the SARS-CoV-2 viral entry, along with ACE2, and has thus become one of the COVID-19 research foci. However, in addition to COVID-19, the current review also summarises its other pathological roles and its involvement in clinical diseases like cancer and neuropathic pain. We also discuss the diversity of native NRP ligands and perform a joint analysis. Last but not least, we review the therapeutic roles of NRP1 and introduce a series of NRP1 modulators, which are typical peptidomimetics or other small molecule antagonists, to provide the medicinal chemistry community with a state-of-the-art overview of neuropilin modulator design and NRP1 druggability assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.